Relugolix Combination Therapy, the 1st GnRH Antagonist in Europe for the management of Uterine Fibroids

P C
21 June 2022
No Comments

Relugolix Combination Therapy, the 1st GnRH Antagonist in Europe for the management of Uterine Fibroids

Relugolix Combination Therapy, the 1st GnRH Antagonist in Europe for the management of Uterine Fibroids https://seud.org/wp-content/uploads/2024/02/2022sympogedeon.jpg 1919 1080 P C P C https://seud.org/wp-content/plugins/ultimate-member/assets/img/default_avatar.jpg 21 June 2022 21 June 2022

Chapters

Relugolix Combination Therapy in women with symptomatic uterine fibroids Ayman Al-Hendy
Management of Bone Mineral Density in Pre-Menopausal Women Peyman Hadji

Relugolix Combination Therapy, the 1st GnRH Antagonist in Europe for the management of Uterine Fibroids

Relugolix Combination Therapy, the 1st GnRH Antagonist in Europe for the management of Uterine Fibroids

Chapters

Hormonal medical management for uterine disorders

Adenomyosis surgery yes… but when? how? How much? By whom?

Contact: SEUD secretariat